KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Tax ProvisionsTax Rate
Others
Ratios

BioNTech SE (BNTX) Income from Continuing Operations (2018 - 2025)

Historic Income from Continuing Operations for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to $91.3 million.

  • BioNTech SE's Income from Continuing Operations fell 5803.26% to $91.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$605.1 million, marking a year-over-year decrease of 98240.58%. This contributed to the annual value of -$737.4 million for FY2024, which is 14753.38% down from last year.
  • As of Q3 2025, BioNTech SE's Income from Continuing Operations stood at $91.3 million, which was down 5803.26% from -$474.1 million recorded in Q2 2025.
  • BioNTech SE's 5-year Income from Continuing Operations high stood at $7.2 billion for Q4 2021, and its period low was -$865.6 million during Q2 2024.
  • Its 5-year average for Income from Continuing Operations is $1.7 billion, with a median of $539.0 million in 2023.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first skyrocketed by 163746041825.11% in 2021, then crashed by 31749.74% in 2024.
  • Over the past 5 years, BioNTech SE's Income from Continuing Operations (Quarter) stood at $7.2 billion in 2021, then tumbled by 67.54% to $2.3 billion in 2022, then tumbled by 59.81% to $934.5 million in 2023, then crashed by 70.32% to $277.3 million in 2024, then plummeted by 67.07% to $91.3 million in 2025.
  • Its last three reported values are $91.3 million in Q3 2025, -$474.1 million for Q2 2025, and -$499.6 million during Q1 2025.